Nayak SU, Griffiss JM, Blumer J, O'Riordan MA, Gray W, McKenzie R, Jurao RA, An AT, Le M, Bell SJ, Ochsner UA, Jarvis TC, Janjic N, Zenilman JM (2017). “Safety, tolerability, systemic exposure and metabolism of CRS3123, a methionyl-tRNA synthetase inhibitor developed for treatment of Clostridium difficile infections, in a Phase I study” Antimicrob Agents Chemother doi:10.1128/AAC.02760-16.

Ochsner UA, Jarvis TC (2013) “Aminoacyl-tRNA Synthetase Inhibitors”, in Antibiotics: Targets, Mechanisms and Resistance (eds Gualerzi CO, Brandi L, Fabbretti A, Pon CL), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527659685.ch16

Critchley IA, Green LS, Young CL, Bullard JM, Evans RJ, Price M, Jarvis TC, Guiles JW, Janjic N, Ochsner UA (2009) “Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections” J Antimicrob Chemother. 63(5):954-63.

Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone KC, Young CL, Critchley IA, Janjic N. (2009) “Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model” J Antimicrob Chemother. 63(5):964-71.

Citron DM1, Warren YA, Tyrrell KL, Merriam V, Goldstein EJ. (2009) “Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria” J Antimicrob Chemother. 63(5):972-6.

Guiles J, Critchley I, Sun X (2008) “New agents for Clostridium difficile-associated disease” Expert Opin Investig Drugs 17(11):1671-83.

Ochsner UA, Sun X, Jarvis T, Critchley I, Janjic N (2007) “Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents” Expert Opin Investig Drugs 16(5):573-93.

Evans RJ, Davies DR, Bullard JM, Christensen J, Green LS, Guiles JW, Pata JD, Ribble WK, Janjic N, Jarvis TC (2008) “Structure of PolC reveals unique DNA binding and fidelity determinants” Proc Natl Acad Sci U S A. 105(52):20695-700.